These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26973413)

  • 1. Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients.
    Gu XQ; Zheng WP; Teng DH; Sun JS; Zheng H
    World J Gastroenterol; 2016 Mar; 22(9):2749-59. PubMed ID: 26973413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
    Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
    Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?
    Moya A; Berenguer M; Aguilera V; Juan FS; Nicolás D; Pastor M; López-Andujar R; Rayón M; Orbis F; Mora J; De Juan M; Carrasco D; Vila JJ; Prieto M; Berenguer J; Mir J
    Liver Transpl; 2002 Nov; 8(11):1020-7. PubMed ID: 12424715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
    Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
    Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
    Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
    Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
    Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
    Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of risk factors for tumor recurrence in hepatitis B and hepatitis C virus-infected patients undergoing liver transplantation for hepatocellular carcinoma.
    Krasnodębski M; Grąt M; Masior Ł; Patkowski W; Krawczyk M
    Ann Transplant; 2015 Feb; 20():70-5. PubMed ID: 25639825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living donor liver transplantation for hepatocellular carcinoma.
    Lee SG; Moon DB
    Recent Results Cancer Res; 2013; 190():165-79. PubMed ID: 22941020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.
    Lee EC; Kim SH; Lee SD; Park H; Lee SA; Park SJ
    World J Gastroenterol; 2016 Apr; 22(14):3803-12. PubMed ID: 27076765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-up Imaging After Liver Transplantation Should Take Into Consideration Primary Hepatocellular Carcinoma Characteristics.
    Dioguardi Burgio M; Ronot M; Fuks D; Dondero F; Cauchy F; Gaujoux S; Dokmak S; Paradis V; Durand F; Belghiti J; Vilgrain V
    Transplantation; 2015 Aug; 99(8):1613-8. PubMed ID: 25710611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
    Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
    Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transplantation for hepatocellular carcinoma.
    Taketomi A; Soejima Y; Yoshizumi T; Uchiyama H; Yamashita Y; Maehara Y
    J Hepatobiliary Pancreat Surg; 2008; 15(2):124-30. PubMed ID: 18392704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria.
    Gao T; Xia Q; Qiu DK; Feng YY; Chi JC; Wang SY; Xi ZF; Zhang JJ; Xu N; Chen SY; Qiu YL; Shen LW; Zhou TT; Dong XJ; Li QG; Li H
    J Dig Dis; 2013 Oct; 14(10):552-8. PubMed ID: 23782458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation.
    Liu B; Teng F; Fu H; Guo WY; Shi XM; Ni ZJ; Gao XG; Ma J; Fu ZR; Ding GS
    BMC Gastroenterol; 2015 Oct; 15():138. PubMed ID: 26472203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.